N 4 (185) 2023. P. 52–55

DIAGNOSTIC IMPORTANCE OF METALLOPROTEINASE ACTIVITY IN THE PREGRAVID PERIOD AND DURING PREGNANCY IN WOMEN WITH A HISTORY OF HEPATOBILIARY DISEASES

I. V. Loskutova, V. G. Marichereda, T. Ia. Moskalenko,
R. G. Bichevska, N. A. Bykova

Donetsk National Medical University, Kropyvnytskyi, Ukraine
Odesa National Medical University, Odesa, Ukraine

DOI https://doi.org/10.32782/2226-2008-2023-4-11

The aim of study. An increase in the concentration of matrix metalloproteinase type 9 (MMP-9) and tissue inhibitor of metalloproteinase type 1 (TIMP-1) in the blood serum during pregnancy in women with a burdened premorbid background indicates their role at the beginning of the placentation process. A significant increase in tissue proteolysis enzyme (MMP-9) with a decrease in the concentration of TIMP-1 in the blood of women with a threat of miscarriage was established, which can be considered a sign of impaired homeostasis of the extracellular matrix.

Materials and methods. In the pregravid period the patients with impaired liver function (non-alcohol steatohepatitis (NASH), liver steatosis) have intensification of lipid peroxidation (an increase of the metabolites in the blood) and insufficiency in the glutathione system, which determines the profound destructive processes at the systemic level. A violation of the lipid spectrum of the blood in the form of hypercholesterolemia and the growth of its atherogenic fractions was observed in the examined patients.

Results. An increase of the MMP-9 level in the blood serum was found in chronic hepatobiliary diseases, and its highest level was detected with exacerbation, which indicated the inflammatory process activation and transformation of steatosis into fibrosis. The concentration of the tissue inhibitor TIMP-1 correlated with the severity of the inflammatory process – the increase in its level is more with NASH than with hepatic steatosis.

Key words: pregravid period, miscarriage, liver steatosis, non-alcohol hepatitis, metalloproteinase type 9, inhibitor of metalloproteinase type 1.

REFERENCES

  1. Golianovsky OV, Zhuravliova LA, Savonik The course of pregnancy, childbirth and the postpartum period in women with the hepatobiliary diseases. Perinatologiia i ftisiologiia. 2016; 3(67): 23–27 (in Ukrainian).
  2. Vorobеva II, Zhуvetska-Denisova AA, Tkachenko VB, Rudakova NV, Tolkach Miscarriage: a current look at the problem (review of the literature). Zdorovie zhenshchiny. 2017; 3(119): 113 (in Ukrainian).
  3. Mikolasevic I, Filipec-Kanizaj T, Jakopcic І et al. Liver Disease During Pregnancy: A Challenging Clinical Issue. Med Sci Monit. 2018; (24): 4080–4090 (in English).
  4. Westbrook RH, Dusheiko G, Williamson Pregnancy and liver disease. J Hepatol. 2016; 64(4): 933–945 (in English).
  5. Hay Liver disease in pregnancy. Hepatology. 2008; 47(3): 1067–1076 (in English).
  6. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan Liver disease in pregnancy. Lancet. 2010; 375(9714): 594–605 (in English).
  7. Grzela K, Litwiniuk M, Zagorska W, Grzela Airway Remodeling in Chronic Obstructive Pulmonary Disease and Asthma: the Role of Matrix Metalloproteinase-9. Arch Immunol Ther Exp(Warsz). 2016; 64(1): 47–55 (in English).
  8. Harris LK, Smith SD, Keogh RJ et Trophoblast- and Vascular Smooth Muscle Cell-Derived MMP-12 Mediates Elastolysis during Uterine Spiral Artery Remodeling. The American Journal of Pathology. 2010; 177(4): 2103–15 (in English).
  9. Filippova Lipid metabolism features in patients with the combination of non-alcoholic steatohepatitis and its correction. Svit medytsyny ta biologii. 2019; 15; 4(70): 172–177 (in English).

Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol. 2016; 111(2): 176–196 (in English).

View article PDF